Skip to main content

Table 1 Base line characteristics of all study patients (n = 84)

From: Nephrotoxicity of cisplatin combination chemotherapy in thoracic malignancy patients with CKD risk factors

Parameter  
Gender  
 Male 65 (77.3 %)
 Female 19 (22.6 %)
Age (y)  
 Median (Range) 61 (33–75)
Performance status  
 0/1/2 41/38/0
 3/4/unknown 1/0/4
Histology  
 Small cell carcinoma 19 (22.6 %)
 Adenocarcinoma 37 (44 %)
 Large-cell carcinoma 2 (2.4 %)
 Squamous cell carcinoma 13 (15.5 %)
 Malignant pleural mesothelioma 6 (7.1 %)
 Thymic malignancy 2 (2.4 %)
 Others 5 (6 %)
Cisplatin  
 Median dose (mg/m2/day) (range) 80 (40–80)
 Median cycle (range) 4 (1–6)
Anticancer drugs  
 Vinorelbine 26 (31 %)
 Etoposide 14 (16.7 %)
 Docetaxel 12 (14.3 %)
 Pemetrexed 11 (13.1 %)
 Gemcitabine 4 (4.8 %)
 S-1 4 (4.8 %)
 Irinotecan 2 (2.4 %)
 Others 11 (13.1 %)
Serum creatinine (mg/dl)  
 Median (range) 0.72 (0.50–0.99)
eGFR (mL/min/1.73 m2)  
 Median (range) 81.1 (59.2–113.0)
Charlson Comorbidity Index  
 Median (range) 6 (2–10)